Skip to content
Screener

Prestige Consumer Healthcare PBH Gastrointestinal — Total revenues

Other product segments

Women's Health
$52.54M-3.7%
Dermatologicals
$33.2M+10.2%
Eye & Ear Care
$32.98M+2.1%
Pain Relief
$26.8M
Oral Care
$22.36M+3.0%
Cough, Cold & Allergy
$21.31M
Wellness, Sleep & Other
$14.33M

Similar metrics at other companies

PROG Holdings logo
PRGOther revenue — Total revenues
$39.4M+134%
Sonida Senior Living logo
SNDAResident revenue — Total revenues
$108.43M+36.8%
Asset Entities logo
ASSTOther revenue — Total revenues
$43K+514%
LanzaTech Global, Inc. logo
LNZABiorefining revenue — Total revenues
$6.98M+145%
ALN
ALNYRoyalty revenue — Total revenues
$71.67M+79.3%
Hyatt Hotels logo
HContra revenue — Total revenues
-$17M-13.3%

Other financials

Income statement

See full
Revenue$265.7M+6.5%
Gross profit$136.2M-3.0%
Operating income$52.5M-26.8%
Net income$29.2M-38.5%
EPS (diluted)$0.61-35.8%

Balance sheet

See full
Cash & equivalents$89.1M-36.1%
Total debt$2.1B+97.4%
Total equity$1.9B+3.3%
Total assets$4.6B+33.1%

Cash flow

See full
Operating cash flow$70.8M-10.4%
CapEx$3.7M+342%
Free cash flow$67.1M-14.2%

Valuation

See full
Market cap$2.58B-30.3%
Enterprise value$4.55B-1.2%
P/E15×-2.4×
P/S2.3×-1.0×

Profitability

See full
Gross margin53.5%-2.6pp
Operating margin26.3%-3.8pp
Net margin15.6%-3.4pp
FCF margin21.3%-2.6pp

Returns & leverage

See full
Return on equity9.1%-2.9pp
Debt / equity1.1×+0.5×
Current ratio3.2×-1.2×

Where this comes from

Reported directly by Prestige Consumer Healthcare in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Prestige Consumer Healthcare’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 6:15 AM EDT
Fiscal quarter
Q1 FY2027
Calendar quarter
Q2 2026
Accession
0001295947-26-000042
(In thousands)Three Months Ended June 30, 2026 / North American OTCHealthcareThree Months Ended June 30, 2026 / International OTCHealthcareConsolidated
Cough, Cold & Allergy$15,628$5,677$21,305
Dermatologicals30,6152,58033,195
Eye & Ear Care28,3394,63932,978
Gastrointestinal47,14115,06162,202
Oral Care18,4583,90022,358
Pain Relief26,22557726,802
Wellness, Sleep & Other12,5591,76814,327
Women's Health47,2415,30252,543

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Prestige Consumer Healthcare's gastrointestinal — total revenues?
Prestige Consumer Healthcare (PBH) reported gastrointestinal — total revenues of $62.2M in Q2 2026.
How has Prestige Consumer Healthcare's gastrointestinal — total revenues changed year-over-year?
Prestige Consumer Healthcare's gastrointestinal — total revenues increased by 7.6% year-over-year, from $57.78M to $62.2M.
What is the long-term trend for Prestige Consumer Healthcare's gastrointestinal — total revenues?
Over 4 years (2022 to 2026), Prestige Consumer Healthcare's gastrointestinal — total revenues has grown at a 6.2% compound annual growth rate (CAGR), from $204.56M to $259.79M.
What does gastrointestinal — total revenues mean?
This metric represents the total gross sales generated by the company's gastrointestinal health product portfolio, which includes over-the-counter treatments for digestive issues. It serves as a key indicator of market demand and brand performance within the specific niche of digestive wellness. Growth in this revenue stream reflects the company's ability to maintain category leadership and effectively capture consumer spending in the gastrointestinal health market.

Ask your AI about Prestige Consumer Healthcare's gastrointestinal — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude